Keith Bley is a veteran drug researcher and developer with core competencies in pharmacology, toxicology, formulation development, regulatory strategy and intellectual property. Most recently, he was Senior Vice President of Product Development at NovaBay Pharmaceuticals, a company that specializes in localized antiinfectives. Previously, he was a co-founder of NeurogesX and led the non-clinical development of the Qutenza¬Æ patch through NDA and the second-generation formulation through a successful Phase 2. Prior to NeurogesX, through ascending roles and responsibilities at Syntex and Roche, he led discovery and development efforts in diverse therapy areas, but with a primary focus in pain and CNS. He currently provides consulting services to a number of Bay Area companies and law firms, while exploring opportunities.
Keith’s PhD is in Molecular and Cellular Physiology from Yale University.